Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.
Identifieur interne : 000351 ( Main/Exploration ); précédent : 000350; suivant : 000352Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.
Auteurs : Ignacio Iturrieta-Zuazo ; Claudia Geraldine Rita ; Ana García-Soidán ; Ana De Malet Pintos-Fonseca ; Nieves Alonso-Alarc N ; Roberto Pariente-Rodríguez ; Amalia Tejeda-Velarde ; Sergio Serrano-Villar ; José Luis Casta Er-Alabau ; Israel Nieto-Ga NSource :
- Clinical immunology (Orlando, Fla.) [ 1521-7035 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Allèles (MeSH), Antigènes d'histocompatibilité de classe I (classification), Antigènes d'histocompatibilité de classe I (génétique), Antigènes d'histocompatibilité de classe I (immunologie), Betacoronavirus (immunologie), Betacoronavirus (pathogénicité), Espagne (MeSH), Expression des gènes (MeSH), Femelle (MeSH), Fréquence d'allèle (MeSH), Humains (MeSH), Immunité innée (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (anatomopathologie), Infections à coronavirus (génétique), Infections à coronavirus (immunologie), Infections à coronavirus (virologie), Interactions hôte-pathogène (immunologie), Liaison aux protéines (MeSH), Mâle (MeSH), Pandémies (MeSH), Peptides (génétique), Peptides (immunologie), Pneumopathie virale (anatomopathologie), Pneumopathie virale (génétique), Pneumopathie virale (immunologie), Pneumopathie virale (virologie), Projets pilotes (MeSH), Protéines virales (génétique), Protéines virales (immunologie), Sujet âgé (MeSH), Évolution de la maladie (MeSH).
- MESH :
- anatomopathologie : Infections à coronavirus, Pneumopathie virale.
- classification : Antigènes d'histocompatibilité de classe I.
- génétique : Antigènes d'histocompatibilité de classe I, Infections à coronavirus, Peptides, Pneumopathie virale, Protéines virales.
- immunologie : Antigènes d'histocompatibilité de classe I, Betacoronavirus, Infections à coronavirus, Interactions hôte-pathogène, Peptides, Pneumopathie virale, Protéines virales.
- pathogénicité : Betacoronavirus.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Adulte, Adulte d'âge moyen, Allèles, Espagne, Expression des gènes, Femelle, Fréquence d'allèle, Humains, Immunité innée, Indice de gravité de la maladie, Liaison aux protéines, Mâle, Pandémies, Projets pilotes, Sujet âgé, Évolution de la maladie.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Alleles (MeSH), Betacoronavirus (immunology), Betacoronavirus (pathogenicity), Coronavirus Infections (genetics), Coronavirus Infections (immunology), Coronavirus Infections (pathology), Coronavirus Infections (virology), Disease Progression (MeSH), Female (MeSH), Gene Expression (MeSH), Gene Frequency (MeSH), Histocompatibility Antigens Class I (classification), Histocompatibility Antigens Class I (genetics), Histocompatibility Antigens Class I (immunology), Host-Pathogen Interactions (immunology), Humans (MeSH), Immunity, Innate (MeSH), Male (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Peptides (genetics), Peptides (immunology), Pilot Projects (MeSH), Pneumonia, Viral (genetics), Pneumonia, Viral (immunology), Pneumonia, Viral (pathology), Pneumonia, Viral (virology), Protein Binding (MeSH), Severity of Illness Index (MeSH), Spain (MeSH), Viral Proteins (genetics), Viral Proteins (immunology).
- MESH :
- chemical , classification : Histocompatibility Antigens Class I.
- chemical , genetics : Viral Proteins.
- chemical , immunology : Viral Proteins.
- geographic : Spain.
- genetics : Coronavirus Infections, Histocompatibility Antigens Class I, Peptides, Pneumonia, Viral.
- immunology : Betacoronavirus, Coronavirus Infections, Histocompatibility Antigens Class I, Host-Pathogen Interactions, Peptides, Pneumonia, Viral.
- pathogenicity : Betacoronavirus.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Aged, Alleles, Disease Progression, Female, Gene Expression, Gene Frequency, Humans, Immunity, Innate, Male, Middle Aged, Pandemics, Pilot Projects, Protein Binding, Severity of Illness Index.
Abstract
Human Leukocyte Antigen (HLA) includes a large set of genes with important actions in immune response against viral infection. Numerous studies have revealed the existence of significant associations between certain HLA alleles and the susceptibility and prognosis of different infectious diseases. In this pilot study we analyse the binding affinity between 66 class I HLA alleles and SARS-CoV-2 viral peptides, and its association with the severity of the disease. A total of 45 Spanish patients with mild, moderate and severe SARS-CoV-2 infection were typed for HLA class I; after that, we analysed if an in silico model of HLA I-viral peptide binding affinity and classical HLA supertypes could be correlated to the severity of the disease. Our results suggest that patients with mild disease present Class I HLA molecules with a higher theoretical capacity for binding SARS-Cov-2 peptides and showed greater heterozygosity when comparing them with moderate and severe groups. In this regard, identifying HLA-SARS-CoV-2 peptides binding differences between individuals would help to clarify the heterogeneity of clinical responses to the disease and will also be useful to guide a personalized treatment according to its particular risk.
DOI: 10.1016/j.clim.2020.108572
PubMed: 32810602
PubMed Central: PMC7428760
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.</title><author><name sortKey="Iturrieta Zuazo, Ignacio" sort="Iturrieta Zuazo, Ignacio" uniqKey="Iturrieta Zuazo I" first="Ignacio" last="Iturrieta-Zuazo">Ignacio Iturrieta-Zuazo</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Rita, Claudia Geraldine" sort="Rita, Claudia Geraldine" uniqKey="Rita C" first="Claudia Geraldine" last="Rita">Claudia Geraldine Rita</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Garcia Soidan, Ana" sort="Garcia Soidan, Ana" uniqKey="Garcia Soidan A" first="Ana" last="García-Soidán">Ana García-Soidán</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="De Malet Pintos Fonseca, Ana" sort="De Malet Pintos Fonseca, Ana" uniqKey="De Malet Pintos Fonseca A" first="Ana" last="De Malet Pintos-Fonseca">Ana De Malet Pintos-Fonseca</name><affiliation><nlm:affiliation>Microbiology Department. Hospital Universitario Marqués de Valdecilla. Santander. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Microbiology Department. Hospital Universitario Marqués de Valdecilla. Santander. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Alonso Alarc N, Nieves" sort="Alonso Alarc N, Nieves" uniqKey="Alonso Alarc N N" first="Nieves" last="Alonso-Alarc N">Nieves Alonso-Alarc N</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Pariente Rodriguez, Roberto" sort="Pariente Rodriguez, Roberto" uniqKey="Pariente Rodriguez R" first="Roberto" last="Pariente-Rodríguez">Roberto Pariente-Rodríguez</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Tejeda Velarde, Amalia" sort="Tejeda Velarde, Amalia" uniqKey="Tejeda Velarde A" first="Amalia" last="Tejeda-Velarde">Amalia Tejeda-Velarde</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Serrano Villar, Sergio" sort="Serrano Villar, Sergio" uniqKey="Serrano Villar S" first="Sergio" last="Serrano-Villar">Sergio Serrano-Villar</name><affiliation><nlm:affiliation>Infectious Disease Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Infectious Disease Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Casta Er Alabau, Jose Luis" sort="Casta Er Alabau, Jose Luis" uniqKey="Casta Er Alabau J" first="José Luis" last="Casta Er-Alabau">José Luis Casta Er-Alabau</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Nieto Ga N, Israel" sort="Nieto Ga N, Israel" uniqKey="Nieto Ga N I" first="Israel" last="Nieto-Ga N">Israel Nieto-Ga N</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain. Electronic address: israel.ganan@salud.madrid.org.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain. Electronic address: israel.ganan@salud.madrid.org.</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32810602</idno><idno type="pmid">32810602</idno><idno type="doi">10.1016/j.clim.2020.108572</idno><idno type="pmc">PMC7428760</idno><idno type="wicri:Area/Main/Corpus">000593</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000593</idno><idno type="wicri:Area/Main/Curation">000593</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000593</idno><idno type="wicri:Area/Main/Exploration">000593</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.</title><author><name sortKey="Iturrieta Zuazo, Ignacio" sort="Iturrieta Zuazo, Ignacio" uniqKey="Iturrieta Zuazo I" first="Ignacio" last="Iturrieta-Zuazo">Ignacio Iturrieta-Zuazo</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Rita, Claudia Geraldine" sort="Rita, Claudia Geraldine" uniqKey="Rita C" first="Claudia Geraldine" last="Rita">Claudia Geraldine Rita</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Garcia Soidan, Ana" sort="Garcia Soidan, Ana" uniqKey="Garcia Soidan A" first="Ana" last="García-Soidán">Ana García-Soidán</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="De Malet Pintos Fonseca, Ana" sort="De Malet Pintos Fonseca, Ana" uniqKey="De Malet Pintos Fonseca A" first="Ana" last="De Malet Pintos-Fonseca">Ana De Malet Pintos-Fonseca</name><affiliation><nlm:affiliation>Microbiology Department. Hospital Universitario Marqués de Valdecilla. Santander. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Microbiology Department. Hospital Universitario Marqués de Valdecilla. Santander. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Alonso Alarc N, Nieves" sort="Alonso Alarc N, Nieves" uniqKey="Alonso Alarc N N" first="Nieves" last="Alonso-Alarc N">Nieves Alonso-Alarc N</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Pariente Rodriguez, Roberto" sort="Pariente Rodriguez, Roberto" uniqKey="Pariente Rodriguez R" first="Roberto" last="Pariente-Rodríguez">Roberto Pariente-Rodríguez</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Tejeda Velarde, Amalia" sort="Tejeda Velarde, Amalia" uniqKey="Tejeda Velarde A" first="Amalia" last="Tejeda-Velarde">Amalia Tejeda-Velarde</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Serrano Villar, Sergio" sort="Serrano Villar, Sergio" uniqKey="Serrano Villar S" first="Sergio" last="Serrano-Villar">Sergio Serrano-Villar</name><affiliation><nlm:affiliation>Infectious Disease Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Infectious Disease Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Casta Er Alabau, Jose Luis" sort="Casta Er Alabau, Jose Luis" uniqKey="Casta Er Alabau J" first="José Luis" last="Casta Er-Alabau">José Luis Casta Er-Alabau</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</wicri:noCountry></affiliation></author><author><name sortKey="Nieto Ga N, Israel" sort="Nieto Ga N, Israel" uniqKey="Nieto Ga N I" first="Israel" last="Nieto-Ga N">Israel Nieto-Ga N</name><affiliation><nlm:affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain. Electronic address: israel.ganan@salud.madrid.org.</nlm:affiliation><wicri:noCountry code="no comma">Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain. Electronic address: israel.ganan@salud.madrid.org.</wicri:noCountry></affiliation></author></analytic><series><title level="j">Clinical immunology (Orlando, Fla.)</title><idno type="eISSN">1521-7035</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Alleles (MeSH)</term><term>Betacoronavirus (immunology)</term><term>Betacoronavirus (pathogenicity)</term><term>Coronavirus Infections (genetics)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (virology)</term><term>Disease Progression (MeSH)</term><term>Female (MeSH)</term><term>Gene Expression (MeSH)</term><term>Gene Frequency (MeSH)</term><term>Histocompatibility Antigens Class I (classification)</term><term>Histocompatibility Antigens Class I (genetics)</term><term>Histocompatibility Antigens Class I (immunology)</term><term>Host-Pathogen Interactions (immunology)</term><term>Humans (MeSH)</term><term>Immunity, Innate (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Peptides (genetics)</term><term>Peptides (immunology)</term><term>Pilot Projects (MeSH)</term><term>Pneumonia, Viral (genetics)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (pathology)</term><term>Pneumonia, Viral (virology)</term><term>Protein Binding (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Spain (MeSH)</term><term>Viral Proteins (genetics)</term><term>Viral Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Allèles (MeSH)</term><term>Antigènes d'histocompatibilité de classe I (classification)</term><term>Antigènes d'histocompatibilité de classe I (génétique)</term><term>Antigènes d'histocompatibilité de classe I (immunologie)</term><term>Betacoronavirus (immunologie)</term><term>Betacoronavirus (pathogénicité)</term><term>Espagne (MeSH)</term><term>Expression des gènes (MeSH)</term><term>Femelle (MeSH)</term><term>Fréquence d'allèle (MeSH)</term><term>Humains (MeSH)</term><term>Immunité innée (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (génétique)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (virologie)</term><term>Interactions hôte-pathogène (immunologie)</term><term>Liaison aux protéines (MeSH)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Peptides (génétique)</term><term>Peptides (immunologie)</term><term>Pneumopathie virale (anatomopathologie)</term><term>Pneumopathie virale (génétique)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (virologie)</term><term>Projets pilotes (MeSH)</term><term>Protéines virales (génétique)</term><term>Protéines virales (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Histocompatibility Antigens Class I</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Coronavirus Infections</term><term>Histocompatibility Antigens Class I</term><term>Peptides</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term><term>Infections à coronavirus</term><term>Peptides</term><term>Pneumopathie virale</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term><term>Betacoronavirus</term><term>Infections à coronavirus</term><term>Interactions hôte-pathogène</term><term>Peptides</term><term>Pneumopathie virale</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Histocompatibility Antigens Class I</term><term>Host-Pathogen Interactions</term><term>Peptides</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Alleles</term><term>Disease Progression</term><term>Female</term><term>Gene Expression</term><term>Gene Frequency</term><term>Humans</term><term>Immunity, Innate</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Pilot Projects</term><term>Protein Binding</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Allèles</term><term>Espagne</term><term>Expression des gènes</term><term>Femelle</term><term>Fréquence d'allèle</term><term>Humains</term><term>Immunité innée</term><term>Indice de gravité de la maladie</term><term>Liaison aux protéines</term><term>Mâle</term><term>Pandémies</term><term>Projets pilotes</term><term>Sujet âgé</term><term>Évolution de la maladie</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human Leukocyte Antigen (HLA) includes a large set of genes with important actions in immune response against viral infection. Numerous studies have revealed the existence of significant associations between certain HLA alleles and the susceptibility and prognosis of different infectious diseases. In this pilot study we analyse the binding affinity between 66 class I HLA alleles and SARS-CoV-2 viral peptides, and its association with the severity of the disease. A total of 45 Spanish patients with mild, moderate and severe SARS-CoV-2 infection were typed for HLA class I; after that, we analysed if an in silico model of HLA I-viral peptide binding affinity and classical HLA supertypes could be correlated to the severity of the disease. Our results suggest that patients with mild disease present Class I HLA molecules with a higher theoretical capacity for binding SARS-Cov-2 peptides and showed greater heterozygosity when comparing them with moderate and severe groups. In this regard, identifying HLA-SARS-CoV-2 peptides binding differences between individuals would help to clarify the heterogeneity of clinical responses to the disease and will also be useful to guide a personalized treatment according to its particular risk.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32810602</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-7035</ISSN><JournalIssue CitedMedium="Internet"><Volume>219</Volume><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Clinical immunology (Orlando, Fla.)</Title><ISOAbbreviation>Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.</ArticleTitle><Pagination><MedlinePgn>108572</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1521-6616(20)30732-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clim.2020.108572</ELocationID><Abstract><AbstractText>Human Leukocyte Antigen (HLA) includes a large set of genes with important actions in immune response against viral infection. Numerous studies have revealed the existence of significant associations between certain HLA alleles and the susceptibility and prognosis of different infectious diseases. In this pilot study we analyse the binding affinity between 66 class I HLA alleles and SARS-CoV-2 viral peptides, and its association with the severity of the disease. A total of 45 Spanish patients with mild, moderate and severe SARS-CoV-2 infection were typed for HLA class I; after that, we analysed if an in silico model of HLA I-viral peptide binding affinity and classical HLA supertypes could be correlated to the severity of the disease. Our results suggest that patients with mild disease present Class I HLA molecules with a higher theoretical capacity for binding SARS-Cov-2 peptides and showed greater heterozygosity when comparing them with moderate and severe groups. In this regard, identifying HLA-SARS-CoV-2 peptides binding differences between individuals would help to clarify the heterogeneity of clinical responses to the disease and will also be useful to guide a personalized treatment according to its particular risk.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iturrieta-Zuazo</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rita</LastName><ForeName>Claudia Geraldine</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Soidán</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Malet Pintos-Fonseca</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Microbiology Department. Hospital Universitario Marqués de Valdecilla. Santander. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Alarcón</LastName><ForeName>Nieves</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente-Rodríguez</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tejeda-Velarde</LastName><ForeName>Amalia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano-Villar</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Infectious Disease Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castañer-Alabau</LastName><ForeName>José Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieto-Gañán</LastName><ForeName>Israel</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunology Department. Hospital Universitario Ramón y Cajal. Madrid. Spain. Electronic address: israel.ganan@salud.madrid.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Immunol</MedlineTA><NlmUniqueID>100883537</NlmUniqueID><ISSNLinking>1521-6616</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Evolution disease</Keyword><Keyword MajorTopicYN="Y">HLA class I</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">Viral peptide-MHC class I binding affinity</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest “The authors declare no conflict of interest.”</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32810602</ArticleId><ArticleId IdType="pii">S1521-6616(20)30732-4</ArticleId><ArticleId IdType="doi">10.1016/j.clim.2020.108572</ArticleId><ArticleId IdType="pmc">PMC7428760</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Alonso Alarc N, Nieves" sort="Alonso Alarc N, Nieves" uniqKey="Alonso Alarc N N" first="Nieves" last="Alonso-Alarc N">Nieves Alonso-Alarc N</name><name sortKey="Casta Er Alabau, Jose Luis" sort="Casta Er Alabau, Jose Luis" uniqKey="Casta Er Alabau J" first="José Luis" last="Casta Er-Alabau">José Luis Casta Er-Alabau</name><name sortKey="De Malet Pintos Fonseca, Ana" sort="De Malet Pintos Fonseca, Ana" uniqKey="De Malet Pintos Fonseca A" first="Ana" last="De Malet Pintos-Fonseca">Ana De Malet Pintos-Fonseca</name><name sortKey="Garcia Soidan, Ana" sort="Garcia Soidan, Ana" uniqKey="Garcia Soidan A" first="Ana" last="García-Soidán">Ana García-Soidán</name><name sortKey="Iturrieta Zuazo, Ignacio" sort="Iturrieta Zuazo, Ignacio" uniqKey="Iturrieta Zuazo I" first="Ignacio" last="Iturrieta-Zuazo">Ignacio Iturrieta-Zuazo</name><name sortKey="Nieto Ga N, Israel" sort="Nieto Ga N, Israel" uniqKey="Nieto Ga N I" first="Israel" last="Nieto-Ga N">Israel Nieto-Ga N</name><name sortKey="Pariente Rodriguez, Roberto" sort="Pariente Rodriguez, Roberto" uniqKey="Pariente Rodriguez R" first="Roberto" last="Pariente-Rodríguez">Roberto Pariente-Rodríguez</name><name sortKey="Rita, Claudia Geraldine" sort="Rita, Claudia Geraldine" uniqKey="Rita C" first="Claudia Geraldine" last="Rita">Claudia Geraldine Rita</name><name sortKey="Serrano Villar, Sergio" sort="Serrano Villar, Sergio" uniqKey="Serrano Villar S" first="Sergio" last="Serrano-Villar">Sergio Serrano-Villar</name><name sortKey="Tejeda Velarde, Amalia" sort="Tejeda Velarde, Amalia" uniqKey="Tejeda Velarde A" first="Amalia" last="Tejeda-Velarde">Amalia Tejeda-Velarde</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000351 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000351 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32810602
|texte= Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32810602" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |